Cardiac remodeling in obesity
- PMID: 18391168
- PMCID: PMC2915933
- DOI: 10.1152/physrev.00017.2007
Cardiac remodeling in obesity
Abstract
The dramatic increase in the prevalence of obesity and its strong association with cardiovascular disease have resulted in unprecedented interest in understanding the effects of obesity on the cardiovascular system. A consistent, but puzzling clinical observation is that obesity confers an increased susceptibility to the development of cardiac disease, while at the same time affording protection against subsequent mortality (termed the obesity paradox). In this review we focus on evidence available from human and animal model studies and summarize the ways in which obesity can influence structure and function of the heart. We also review current hypotheses regarding mechanisms linking obesity and various aspects of cardiac remodeling. There is currently great interest in the role of adipokines, factors secreted from adipose tissue, and their role in the numerous cardiovascular complications of obesity. Here we focus on the role of leptin and the emerging promise of adiponectin as a cardioprotective agent. The challenge of understanding the association between obesity and heart failure is complicated by the multifaceted interplay between various hemodynamic, metabolic, and other physiological factors that ultimately impact the myocardium. Furthermore, the end result of obesity-associated changes in the myocardial structure and function may vary at distinct stages in the progression of remodeling, may depend on the individual pathophysiology of heart failure, and may even remain undetected for decades before clinical manifestation. Here we summarize our current knowledge of this complex yet intriguing topic.
Figures




Similar articles
-
Direct effects of adipokines on the heart: focus on adiponectin.Heart Fail Rev. 2013 Sep;18(5):631-44. doi: 10.1007/s10741-012-9337-8. Heart Fail Rev. 2013. PMID: 22893246 Review.
-
Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure.Trends Cardiovasc Med. 2008 Aug;18(6):199-205. doi: 10.1016/j.tcm.2008.10.001. Trends Cardiovasc Med. 2008. PMID: 19185809 Review.
-
Hypercaloric diet models do not develop heart failure, but the excess sucrose promotes contractility dysfunction.PLoS One. 2020 Feb 7;15(2):e0228860. doi: 10.1371/journal.pone.0228860. eCollection 2020. PLoS One. 2020. PMID: 32032383 Free PMC article.
-
Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications.Prog Cardiovasc Dis. 2018 Jul-Aug;61(2):114-123. doi: 10.1016/j.pcad.2018.07.012. Epub 2018 Jul 7. Prog Cardiovasc Dis. 2018. PMID: 29990533 Review.
-
[Leptin as a mediator between obesity and cardiac dysfunction].Postepy Hig Med Dosw (Online). 2012 May 23;66:267-74. doi: 10.5604/17322693.997817. Postepy Hig Med Dosw (Online). 2012. PMID: 22706112 Review. Polish.
Cited by
-
Pregnancy-driven cardiovascular maternal miR-29 plasticity in obesity.J Med Primatol. 2016 Dec;45(6):297-303. doi: 10.1111/jmp.12236. Epub 2016 Sep 15. J Med Primatol. 2016. PMID: 27627870 Free PMC article.
-
[Overweight and obesity in the population over 20 years in urban Bamako (Mali)].Pan Afr Med J. 2014 Dec 4;19:352. doi: 10.11604/pamj.2014.19.352.4381. eCollection 2014. Pan Afr Med J. 2014. PMID: 25932065 Free PMC article. French.
-
Matricellular proteins in cardiac adaptation and disease.Physiol Rev. 2012 Apr;92(2):635-88. doi: 10.1152/physrev.00008.2011. Physiol Rev. 2012. PMID: 22535894 Free PMC article. Review.
-
Cluster Differentiating 36 (CD36) Deficiency Attenuates Obesity-Associated Oxidative Stress in the Heart.PLoS One. 2016 May 19;11(5):e0155611. doi: 10.1371/journal.pone.0155611. eCollection 2016. PLoS One. 2016. PMID: 27195707 Free PMC article.
-
Neuroendocrine and cardiac metabolic dysfunction and NLRP3 inflammasome activation in adipose tissue and pancreas following chronic spinal cord injury in the mouse.ASN Neuro. 2013 Sep 4;5(4):243-55. doi: 10.1042/AN20130021. ASN Neuro. 2013. PMID: 23924318 Free PMC article.
References
-
- Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002;283:H949–H957. - PubMed
-
- Aasum E, Cooper M, Severson DL, Larsen TS. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol. 2005;83:183–190. - PubMed
-
- Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003;52:434–441. - PubMed
-
- Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A, Hasegawa K. Leptin induces elongation of cardiac myocyte and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol. 2007;292:H2387–H2396. - PubMed
-
- Abel ED. Insulin signaling in heart muscle: lessons from genetically engineered mouse models. Curr Hypertens Rep. 2004;6:416–423. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical